Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung Ju Ahn

    Research output: Contribution to journalComment/debatepeer-review

    Abstract

    The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.

    Original languageEnglish
    Pages (from-to)1248
    Number of pages1
    JournalJournal of Clinical Oncology
    Volume38
    Issue number11
    DOIs
    Publication statusPublished - 2020 Apr 10

    Bibliographical note

    Publisher Copyright:
    © 2020 American Society of Clinical Oncology. All rights reserved.

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)'. Together they form a unique fingerprint.

    Cite this